ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
-8.36%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$321M
AUM Growth
+$321M
(-4.3%)
Cap. Flow
+$14.4M
Cap. Flow
% of AUM
4.47%
Top 10 Holdings %
Top 10 Hldgs %
44.07%
Holding
97
New
19
Increased
18
Reduced
17
Closed
33
Top Buys
| 1 |
Establishment Labs
ESTA
|
$8.02M |
| 2 |
Biohaven
BHVN
|
$6.54M |
| 3 |
argenx
ARGX
|
$6.15M |
| 4 |
RxSight
RXST
|
$5.95M |
| 5 |
ResMed
RMD
|
$5.95M |
Top Sells
| 1 |
Vera Therapeutics
VERA
|
$10.7M |
| 2 |
Vaxcyte
PCVX
|
$8.23M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.6M |
| 4 |
iRhythm Technologies
IRTC
|
$6.38M |
| 5 |
Glaukos
GKOS
|
$5.55M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Consumer Staples | 0.09% |
| 3 | Consumer Discretionary | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$4.12B
| $23.9M | 6.79% | 1,395,000 +35,000 | +3% | +$600K |
|
|
2
Vera Therapeutics
VERA
$1.38B
| $18.3M | 5.18% | 432,000 -252,000 | -37% | -$10.7M |
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $15.4M | 4.38% | 127,000 -43,000 | -25% | -$5.23M |
|
4
Zevra Therapeutics
ZVRA
$509M
| $15.4M | 4.38% | 1,850,000 +150,000 | +9% | +$1.25M |
|
|
5
Establishment Labs
ESTA
$1.2B
| $14.1M | 3.99% | 305,000 +174,000 | +133% | +$8.02M |
|
6
Edwards Lifesciences
EW
$47.8B
| $12.2M | 3.46% | 165,000 -57,000 | -26% | -$4.22M |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $11.3M | 3.2% | 288,000 -72,600 | -20% | -$2.85M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $11.2M | 3.19% | 250,000 +37,091 | +17% | +$1.67M |
|
9
Capricor Therapeutics
CAPR
$287M
| $9.85M | 2.79% | 714,000 +429,000 | +151% | +$5.92M |
|
|
10
RxSight
RXST
$370M
| $9.8M | 2.78% | 285,000 +173,000 | +154% | +$5.95M |
|
11
Merit Medical Systems
MMSI
$5.36B
| $9.67M | 2.74% | 100,000 +15,000 | +18% | +$1.45M |
|
|
12
Biohaven
BHVN
$1.63B
| $9.34M | 2.65% | 250,000 +175,000 | +233% | +$6.54M |
|
13
Insmed
INSM
$28.8B
| $9.11M | 2.58% | 132,000 +2,000 | +2% | +$138K |
|
14
Rezolute
RZLT
$619M
| $8.3M | 2.35% | 1,694,000 -6,000 | -0.4% | -$29.4K |
|
15
Evolus
EOLS
$494M
| $7.56M | 2.15% | 685,000 +330,000 | +93% | +$3.64M |
|
|
ITCI
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.26M | 1.78% | 75,000 -79,000 | -51% | -$6.6M |
|
|
17
argenx
ARGX
$43.6B
| $6.15M | 1.74% | +10,000 | New | +$6.15M |
|
|
18
Glaukos
GKOS
$5.5B
| $6M | 1.7% | 40,000 -37,000 | -48% | -$5.55M |
|
|
19
ResMed
RMD
$40.2B
| $5.95M | 1.69% | +26,000 | New | +$5.95M |
|
20
Viking Therapeutics
VKTX
$3.04B
| $5.88M | 1.67% | 146,000 +20,000 | +16% | +$805K |
|
21
Exact Sciences
EXAS
$8.98B
| $5.62M | 1.59% | +100,000 | New | +$5.62M |
|
22
Pulmonx
LUNG
$69.7M
| $5.53M | 1.57% | 815,000 +315,000 | +63% | +$2.14M |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $5.38M | 1.53% | +1,424,400 | New | +$5.38M |
|
24
Catalyst Pharmaceutical
CPRX
$2.52B
| $5.32M | 1.51% | 255,000 -130,000 | -34% | -$2.71M |
|
|
CTNM
25
Contineum Therapeutics
CTNM
$293M
| $4.89M | 1.39% | 334,000 -35,126 | -10% | -$515K |
|